The U.S. Centers for Disease Control and Prevention (CDC) has revised its guidance on COVID-19 vaccines for children, stating that vaccination for healthy individuals aged 6 months to 17 years should follow a “shared clinical decision-making” process. This means that shots are still available, but only if parents and doctors agree it's necessary based on individual circumstances.
The move marks a shift from earlier CDC guidance, which broadly recommended updated COVID-19 vaccines for everyone six months and older. The updated schedule, published Thursday, outlines that if parents want their child vaccinated, they may proceed based on a healthcare provider’s judgment and the family’s preference.
Health Secretary Robert F. Kennedy Jr., a known vaccine skeptic, claimed earlier in the week that COVID vaccines for healthy children and pregnant women had been removed from the CDC’s immunization schedule. However, a Department of Health and Human Services spokesperson said there is no contradiction, as the CDC’s updated guidance no longer promotes universal vaccination for healthy children but still allows it case-by-case.
Medical experts criticized Kennedy’s unilateral announcement, saying it bypassed the CDC’s usual advisory process. The Infectious Diseases Society of America warned the change may limit access and insurance coverage, especially for vulnerable children. They emphasized that COVID-19 can cause serious illness in children, including long COVID symptoms that may impact development.
According to CDC data, nearly 1,900 children under 18 have died from COVID-19 in the U.S. as of 2023. Vaccine makers Pfizer, Moderna, and Novavax have not commented on the development.
The FDA also recently announced it would require new clinical trials for annual COVID boosters in healthy individuals under 65, reinforcing a more limited use strategy moving forward.


GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
Trump Pushes Back on 401(k) Homebuyer Plan Amid Housing Affordability Debate
More Than 100 Venezuelan Political Prisoners Released Amid Ongoing Human Rights Scrutiny
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms 



